Sex Differences in CKD-Associated Mortality From 1990 to 2019: Data From the Global Burden of Disease Study.

RATIONALE & OBJECTIVE: Previous studies have shown chronic kidney disease (CKD) mortality rates to be lower among females than males. We aimed to examine the extent to which sex differences vary over time, among countries, and with age, using Global Burden of Disease (GBD) Study data.

STUDY DESIGN

Observational epidemiological study.

SETTING & PARTICIPANTS: GBD Study, which used published literature, vital registration systems, kidney replacement therapy registries, and household surveys.

EXPOSURES

Sex.

OUTCOMES

CKD-associated mortality rate (per 100,000 population).

ANALYTICAL APPROACH

Changes in CKD mortality between 1990 and 2019 were compared between sexes, globally, and separately for the 50 most populous countries. For 2019 only, sex differences in age-standardized and age-specific mortality were compared between countries.

RESULTS

There was no change in global age-standardized mortality for either sex between 1990 and 2019, with female mortality consistently 30% lower than male mortality. Percentage changes were less favorable among females than males in two-thirds of the 50 countries examined, with the greatest change disparities observed in Egypt, Thailand, and Malaysia. Although Mexico exhibited the greatest overall percentage increase, the increase was smaller in females (81% vs 138%). In 2019, female mortality varied between 47% lower and 60% higher than male mortality (in Angola and Egypt, respectively). In most countries, female mortality was lower across all age groups, with no narrowing of sex differences with age.

LIMITATIONS

We were not able to assess the sex differences according to CKD stage and we did not explore other disease metrics (eg, disability-adjusted life years).

CONCLUSIONS

Percentage changes in age-standardized CKD mortality have tended to be less favorable among females than males, with notable exceptions. Similarly, although female mortality is generally lower than male mortality, there are multiple examples of the opposite. Country-specific assessments of sex differences in CKD-associated outcomes are essential for equitable care.